32282-06-7

Usage

Uses

Used in Pharmaceutical Industry:
N-Ethyl-2,3-Pyridinediamine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and enhance their properties.
Used in Dye Industry:
N-Ethyl-2,3-Pyridinediamine is used as an intermediate in the synthesis of dyes, contributing to the creation of a wide range of colorants for various applications.
Used in Organic Compounds Synthesis:
N-Ethyl-2,3-Pyridinediamine is used as an intermediate in the synthesis of other organic compounds, playing a crucial role in the production of various chemical products.
Used in Water Treatment Chemicals Industry:
N-Ethyl-2,3-Pyridinediamine is used as a corrosion inhibitor in the manufacturing of water treatment chemicals, helping to prevent the deterioration of materials in contact with water and ensuring the longevity and efficiency of water systems.

InChI:InChI=1/C7H11N3/c1-2-9-7-6(8)4-3-5-10-7/h3-5H,2,8H2,1H3,(H,9,10)

Upstream product

• 99314-99-5 2-acetylamino-3-aminopyridine 
• 26820-65-5 ethyl-(3-nitropyridin-2-yl)amine 
• 452-58-4 2,3-Diaminopyridine 
• 99314-93-9 N²-acetyl-N³-benzyloxycarbonyl-2,3-diaminopyridine 
• 99314-92-8 N²-amino-N³-benzyloxycarbonylaminopyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 

Downstream Products

• 380378-90-5 [2-chloro-N-{2-(ethylamino)-3-pyridinyl}-5-bromo-3-] pyridinecarboxamide 
• 1399050-23-7 N₂-ethyl-N₃-phenylpyridine-2,3-diamine 
• 1399050-24-8 3-chloro-3-ethyl-1-phenyl-2,3-dihydro-1H-imidazo[4,5-b]pyridine-3-ium-2-ide 
• 448211-19-6 1-ethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one 
• 78686-86-9 5-bromo-2-chloro-pyridine-3-carbonyl chloride 
• 1028254-47-8 2-(2-Amino-phenylethynyl)-5-ethyl-10-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one 
• 1026854-16-9 5-Ethyl-10-methyl-2-o-tolylethynyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one 
• 1026873-42-6 2-[(E)-2-(4-Amino-phenyl)-vinyl]-5-ethyl-10-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one 
• 189393-20-2 5,11-Dihydro-11-ethyl-5-methyl-8-phenylethynyl-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one 

Relevant academic research and scientific papers

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands

It is getting clearer that many drugs effective in different therapeutic areas act on multiple rather than single targets. The application of polypharmacology concepts might have numerous advantages especially for disease such as HIV/AIDS, where the rapid emergence of resistance requires a complex combination of more than one drug. In this paper, we have designed three hybrid molecules combining WM5, a quinolone derivative we previously identified as HIV Tat-mediated transcription (TMT) inhibitor, with the tricyclic core of nevirapine and BILR 355BS (BILR) non-nucleoside reverse transcriptase inhibitors (NNRTIs) to investigate whether it could be possible to obtain molecules acting on both transcription steps of the HIV replicative cycle. One among the three designed multiple ligands, reached this goal. Indeed, compound 1 inhibited both TMT and reverse transcriptase (RT) activity. Unexpectedly, while the anti-TMT activity exerted by compound 1 resulted into a selective inhibition of HIV-1 reactivation from latently infected OM10.1 cells, the anti-RT properties shown by all of the synthesized compounds did not translate into an anti-HIV activity in acutely infected cells. Thus, we have herein produced the proof of concept that the design of dual TMT-RT inhibitors is indeed possible, but optimization efforts are needed to obtain more potent derivatives.

PYRIDYL CARBENE PHOSPHORESCENT EMITTERS

Organometallic compounds comprising an imidazole carbene ligand having a N- containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen

PYRIDYL CARBENE PHOSPHORESCENT EMITTERS

Organometallic compounds comprising an imidazole carbene ligand having a N-containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen a

HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY

The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Compounds represented by formula (1), wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or methyl; R3 is H or (C1-4)alkyl; R4 is H or (C1-4)a

Non-nucleoside reverse transcriptase inhibitors

Compounds represented by formula I: wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or (C1-4)alkyl; R3 is H or (C1-4)alkyl; R4 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cycloalkyl, or (C3-7)cycloalkyl; and Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q being optionally substituted with hydroxy, or (C1-4)alkyl which in turn maybe optionally substituted with pyridinyl-N-oxide or C(O)OR wherein R is H or (C1-4)alkyl; or a salt thereof. The compounds have inhibitory activity against Wild Type, and single and double mutants strains, of HIV.

Non-nucleoside reverse transcriptase inhibitors

Provided are compounds of the general formula I: wherein R2 is selected from the group consisting of H, F, Cl, (C1-4) alkyl, (C3-4) cycloalkyl and CF3; R4 is H or Me; R5 is H, Me or Et, wit

8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido?3,2-B:2',3'-e!?1!diazepines and their use in the treatment of HIV-1 infection

Disclosed are novel 8-arylalkyl-5,11-dihydro-6H-dipyrido?3,2-b:2',3'-e!?1,4!diazepines. These are useful in the treatment of HIV-1 infection.

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8- Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild- type and mutant enzymes

Like other nonnucleoside inhibitors of HIV-1 reverse transcriptase, the dipyridodiazepinone nevirapine (Viramune, 1) selects for drug resistant variants of HIV-1, both in cell culture and in patients. In particular, the mutation of residue 181 from tyrosine to cysteine (Y181C) is associated with resistance to most reported nonnucleoside inhibitors. Introduction of an arylethyl substituent at the 8-position of the tricyclic dipyridodiazepinone skeleton confers enhanced potency against Y181C RT. Several analogues of this series display good broad spectrum potency against a panel of mutant enzymes.